Drug Profile
LY 545694
Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Kainic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Musculoskeletal pain; Neuropathic pain
Most Recent Events
- 08 Sep 2015 No recent reports on development identified - Phase-II for Musculoskeletal pain in USA (PO)
- 08 Sep 2015 No recent reports on development identified - Phase-II for Neuropathic pain in Puerto Rico, Mexico and USA (PO)
- 30 Jun 2010 Eli Lilly and Company completes phase II trials in Neuropathic pain and Musculoskeletal pain